Does previous asbestos exposure increase the risk of a post coronary artery bypass graft (CABG) pleural effusion - a routine data study?
Asbestos
Coronary artery bypass graft
Pleura
Pleural effusion
Pleural plaque
Routine data
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
21 Aug 2023
21 Aug 2023
Historique:
received:
11
05
2023
accepted:
06
07
2023
medline:
23
8
2023
pubmed:
22
8
2023
entrez:
22
8
2023
Statut:
epublish
Résumé
Development of pleural effusion (PE) following CABG is common. Post-CABG PE are divided into early- (within 30 days of surgery) and delayed-onset (30 days-1 year) which are likely due to distinct pathological processes. Some experts suggest asbestos exposure may confer an independent risk for late-onset post-CABG PE, however no large studies have explored this potential association. To explore possible association between asbestos exposure and post-CABG PE using routine data. All patients who underwent CABG 01/04/2013-31/03/2018 were identified from the Hospital Episode Statistics (HES) Database. This England-wide population was evaluated for evidence of asbestos exposure, pleural plaques or asbestosis and a diagnosis of PE or PE-related procedure from 30 days to 1 year post-CABG. Patients with evidence of PE three months prior to CABG were excluded, as were patients with a new mesothelioma diagnosis. 68,150 patients were identified, of whom 1,003 (1%) were asbestos exposed and 2,377 (3%) developed late-onset PE. After adjusting for demographic data, Index of Multiple Deprivation and Charlson Co-morbidity Index, asbestos exposed patients had increased odds of PE diagnosis or related procedure such as thoracentesis or drainage (OR 1.35, 95% CI 1.03-1.76, p = 0.04). In those with evidence of PE requiring procedure alone, the adjusted OR was 1.66 (95% CI 1.14-2.40, p = 0.01). Additional subgroup analysis of the 518 patients coded for pleural plaques and asbestosis alone revealed an adjusted OR of post-CABG PE requiring a procedure of 2.16 (95% CI 1.38-3.37, p = 0.002). This large-scale study demonstrates prior asbestos exposure is associated with modestly increased risk of post-CABG PE development. The risk association appears higher in patients with assigned clinical codes indicative of radiological evidence of asbestos exposure (pleural plaques or asbestosis). This association may fit with a possible inflammatory co-pathogenesis, with asbestos exposure 'priming' the pleura resulting in greater propensity for PE evolution following the physiological insult of CABG surgery. Further work, including prospective studies and clinicopathological correlation are suggested to explore this further.
Sections du résumé
BACKGROUND
BACKGROUND
Development of pleural effusion (PE) following CABG is common. Post-CABG PE are divided into early- (within 30 days of surgery) and delayed-onset (30 days-1 year) which are likely due to distinct pathological processes. Some experts suggest asbestos exposure may confer an independent risk for late-onset post-CABG PE, however no large studies have explored this potential association.
RESEARCH QUESTION
OBJECTIVE
To explore possible association between asbestos exposure and post-CABG PE using routine data.
METHODS
METHODS
All patients who underwent CABG 01/04/2013-31/03/2018 were identified from the Hospital Episode Statistics (HES) Database. This England-wide population was evaluated for evidence of asbestos exposure, pleural plaques or asbestosis and a diagnosis of PE or PE-related procedure from 30 days to 1 year post-CABG. Patients with evidence of PE three months prior to CABG were excluded, as were patients with a new mesothelioma diagnosis.
RESULTS
RESULTS
68,150 patients were identified, of whom 1,003 (1%) were asbestos exposed and 2,377 (3%) developed late-onset PE. After adjusting for demographic data, Index of Multiple Deprivation and Charlson Co-morbidity Index, asbestos exposed patients had increased odds of PE diagnosis or related procedure such as thoracentesis or drainage (OR 1.35, 95% CI 1.03-1.76, p = 0.04). In those with evidence of PE requiring procedure alone, the adjusted OR was 1.66 (95% CI 1.14-2.40, p = 0.01). Additional subgroup analysis of the 518 patients coded for pleural plaques and asbestosis alone revealed an adjusted OR of post-CABG PE requiring a procedure of 2.16 (95% CI 1.38-3.37, p = 0.002).
INTERPRETATION
CONCLUSIONS
This large-scale study demonstrates prior asbestos exposure is associated with modestly increased risk of post-CABG PE development. The risk association appears higher in patients with assigned clinical codes indicative of radiological evidence of asbestos exposure (pleural plaques or asbestosis). This association may fit with a possible inflammatory co-pathogenesis, with asbestos exposure 'priming' the pleura resulting in greater propensity for PE evolution following the physiological insult of CABG surgery. Further work, including prospective studies and clinicopathological correlation are suggested to explore this further.
Identifiants
pubmed: 37605147
doi: 10.1186/s12890-023-02555-9
pii: 10.1186/s12890-023-02555-9
pmc: PMC10441712
doi:
Substances chimiques
Asbestos
1332-21-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
307Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Am J Respir Crit Care Med. 1996 Sep;154(3 Pt 1):789-93
pubmed: 8810620
Chest. 1988 Jul;94(1):68-71
pubmed: 2898323
Anesthesiol Clin North Am. 2003 Sep;21(3):675-89
pubmed: 14562572
Respirology. 2004 Nov;9(4):441-7
pubmed: 15612954
Eur Heart J. 2004 Apr;25(7):587-610
pubmed: 15120056
Int J Cardiol. 2018 Nov 1;270:89-95
pubmed: 30219542
Med Clin North Am. 2011 Nov;95(6):1055-70
pubmed: 22032427
Chest. 2009 Dec;136(6):1604-1611
pubmed: 19581352
Ann Intern Med. 1999 Jun 1;130(11):891-6
pubmed: 10375337
Radiol Case Rep. 2021 Oct 27;17(1):1-4
pubmed: 34754347
Heart Vessels. 2007 Jan;22(1):16-20
pubmed: 17285440
Pharmacoeconomics. 2016 Feb;34(2):161-8
pubmed: 26386702
Ann Thorac Surg. 1990 Dec;50(6):959-64
pubmed: 2241387
Med J Aust. 2011 Sep 5;195(5):271-4
pubmed: 21895596
Rev Port Pneumol. 2006 Jul-Aug;12(4):359-67
pubmed: 16969568
Curr Opin Pulm Med. 2002 Jul;8(4):308-11
pubmed: 12055394
PLoS One. 2017 Mar 6;12(3):e0172814
pubmed: 28263996
Int J Occup Environ Health. 2015;21(2):169-71
pubmed: 25582748
Clin Chest Med. 2006 Jun;27(2):267-83
pubmed: 16716818
Arch Intern Med. 2000 Sep 25;160(17):2665-8
pubmed: 10999982
BMJ. 2005 Apr 23;330(7497):960-2
pubmed: 15845982
Environ Health. 2018 Dec 19;17(1):90
pubmed: 30567579
Thorax. 2007 Nov;62 Suppl 2:ii1-ii19
pubmed: 17965072
Respirology. 2007 Jan;12(1):122-6
pubmed: 17207037
Chest. 2001 Mar;119(3):795-800
pubmed: 11243959
Science. 1989 Dec 8;246(4935):1306-9
pubmed: 2479986
Lancet Oncol. 2009 May;10(5):453-4
pubmed: 19418618
BMJ Open. 2019 Mar 23;9(3):e023316
pubmed: 30904838
Eur Respir J. 1997 Dec;10(12):2898-901
pubmed: 9493681
Rev Port Pneumol. 2007 May-Jun;13(3):319-34
pubmed: 17632672